These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effects of antacids on the absorption of enteric-coated phenylbutazone (butacote). Downie WW; Lowe JR; Pickup ME J Int Med Res; 1977; 5 Suppl 2():20-5. PubMed ID: 913870 [TBL] [Abstract][Full Text] [Related]
3. [Studies of gastric tolerance of coated alka-butazolidin tablets]. Richter H; Atefie K; Gangl A; Thumb N Wien Z Inn Med; 1970; 51(9):430-6. PubMed ID: 5316365 [No Abstract] [Full Text] [Related]
4. [Improved compatibility of phenylbutazone drugs. A new antirheumatic agent in sugar-coated tablets, suppositories, ampoules]. Dürrigl T; Vitaus M Munch Med Wochenschr; 1969 Mar; 111(10):564-8. PubMed ID: 4239143 [No Abstract] [Full Text] [Related]
7. [Enteric-coated phenylbutazone in the treatment of rheumatic conditions in patients prone to gastric irritation (author's transl)]. Mauracher EH Schweiz Rundsch Med Prax; 1975 Dec; 64(51):1644-7. PubMed ID: 765998 [No Abstract] [Full Text] [Related]
8. Butacote: a six-year follow-up of patients with gastric intolerance to other medications. Cardoe N; Fowler PD J Int Med Res; 1977; 5 Suppl 2():59-66. PubMed ID: 334606 [No Abstract] [Full Text] [Related]
9. Phenylbutazone and hepatitis. Fowler PD; Woolf D; Alexander S Rheumatol Rehabil; 1975 May; 14(2):71-5. PubMed ID: 1145012 [TBL] [Abstract][Full Text] [Related]
10. Bioavailability of phenylbutazone from a new enteric-coated formulation with superior dissolution characteristics. John VA; Goldsborough S; Morrison PJ; Rogers HJ; Spector RG; Bradbrook ID Biopharm Drug Dispos; 1982; 3(1):67-74. PubMed ID: 7082780 [TBL] [Abstract][Full Text] [Related]
11. How do I administer medication by NG? Birdsall C; Uretsky S Am J Nurs; 1984 Oct; 84(10):1259-60, 1284. PubMed ID: 6435450 [No Abstract] [Full Text] [Related]
12. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations. Turakka H; Airaksinen MM Ann Clin Res; 1974; 6(0):suppl 11:34-43. PubMed ID: 4855463 [No Abstract] [Full Text] [Related]
13. [Absorption of the drug-contents of enteric-coated tablets]. Tikkanen R Nord Med; 1967 Nov; 78(47):1564-7. PubMed ID: 6075282 [No Abstract] [Full Text] [Related]
14. The effect of food on the absorption of phenylbutazone from a commercial 100 mg enteric-coated tablet. John VA; Monk JP J Clin Hosp Pharm; 1982 Sep; 7(3):175-9. PubMed ID: 7174832 [TBL] [Abstract][Full Text] [Related]
15. The physiologic availability of phenylbutazone tablets marketed in India. Manek SP; Tipnis HP; Kulkarni RD Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):163-7. PubMed ID: 7263103 [TBL] [Abstract][Full Text] [Related]
16. Interaction of omeprazole with enteric-coated salicylate tablets. Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060 [TBL] [Abstract][Full Text] [Related]
17. Absorption of phenylbutazone from entericcoated and regular tablets. Pantio M; Strandman D; Tikkanen R Acta Rheumatol Scand; 1968; 14(2):113-20. PubMed ID: 5728579 [No Abstract] [Full Text] [Related]
18. [Concentrations of phenylbutazone in the blood following use of Butazolidin ointment]. Hansen EC; Nielsen E Ugeskr Laeger; 1972 Jan; 134(5):208-10. PubMed ID: 5010808 [No Abstract] [Full Text] [Related]